FDA restructuring
This article was originally published in The Tan Sheet
Executive Summary
Office of Pediatric Drug Development & Special Initiatives, forming Oct. 1, will be headed by ODE IV Director Dianne Murphy, MD. Division of Special Pathogenic & Immunologic Drug Products Director Mark Goldberger, MD, will take over as ODE IV acting director. The office will assist with pediatric drug policy and regulatory support, handle "initiatives related to the study and labeling of drugs in pregnancy" and serve as a liaison with external pediatric advocacy groups, CDER says. Originally slated to be the Office of Pediatric Therapeutics, the office reflects the upsurge in pediatric clinical trials following passage of FDAMA's pediatric exclusivity provisions (1"The Tan Sheet" July 16, p. 16)
You may also be interested in...
FDA Pediatric Therapeutics Office Could Fall Under ORM Purview
FDA's Office of Pediatric Therapeutics would be located within the Office of Review Management under proposed organizational changes at the agency.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands